Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling

Cardiovascular Research

Volumn 67, Issue 1, 2005, Pages 106-115

  Gurantz, Devorah ^a   Yndestad, Arne ^b   Halvorsen, Bente ^b   Lunde, Ottar V ^a   Omens, Jeffrey H ^a   Ueland, Thor ^b   Aukrust, Pål ^b,c   Moore, Cristina D ^a   Kjekshus, John ^a,c   Greenberg, Barry H ^a  

^a UCSD MEDICAL CENTER   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cytokines; Infarction; Remodeling

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DRUG VEHICLE; ETANERCEPT; GELATINASE A; IMMUNOGLOBULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DISEASE COURSE; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE PRESSURE; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; IMMUNOMODULATION; LEFT CORONARY ARTERY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ANIMALS; COLLAGEN; CYTOKINES; FIBROSIS; GENE EXPRESSION REGULATION; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 20444411498     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2005.02.016     Document Type: Article

References (33)

1. N.G. Frangogiannis, C.W. Smith, and M.L. Entman The inflammatory response in myocardial infarction Cardiovasc Res 53 2002 31 47
2. S. Sasayama, A. Matsumori, and Y. Kihara New insights into the pathophysiological role for cytokines in heart failure Cardiovasc Res 42 1999 557 564
3. T. Yokoyama, M. Nakano, J.L. Bednarczyk, B.W. McIntyre, M. Entman, and D.L. Mann Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes Circulation 95 1997 1247 1252
4. D.L. Mann Inflammatory mediators and the failing heart-past, present, and the foreseeable future Circ Res 91 2002 988 998
5. W.S. Bradham, G. Moe, K.A. Wendt, A.A. Scott, A. Konig, and M. Romanova TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling Am J Physiol Heart Circ Physiol 282 2002 H1288 H1295
6. N. Sivasubramanian, M.L. Coker, K.M. Kurrelmeyer, W.R. MacLellan, F.J. DeMayo, and F.G. Spinale Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor Circulation 104 2001 826 831
7. B. Bozkurt, G. Torre-Amione, M.S. Warren, J. Whitmore, O.Z. Soran, and A.M. Feldman Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure Circulation 103 2001 1044 1047
8. L. Gullestad, H. Aass, J.G. Fjeld, L. Wikeby, A.K. Andreassen, and H. Ihlen Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure Circulation 103 2001 220 225
9. M. Ballow Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases J Allergy Clin Immunol 100 1997 151 157
10. J.H. Omens, T.R. Miller, and J.W. Covell Relationship between passive tissue strain and collagen uncoiling during healing of infarcted myocardium Cardiovasc Res 33 1997 351 358
11. K. Krasinski, I. Spyridopoulos, M. Kearney, and D.W. Losordo In vivo blockade of tumor necrosis factor-alpha accelerates functional endothelial recovery after balloon angioplasty Circulation 104 2001 1754 1756
12. B. Bozkurt, S.B. Kribbs, F.J. Clubb Jr., L.H. Michael, V.V. Didenko, and P.J. Hornsby Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats Circulation 97 1998 1382 1391
13. J.T. Peterson, H. Li, L. Dillon, and J.W. Bryant Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat Cardiovasc Res 46 2000 307 315
14. J. Ambrose, D.G. Pribnow, G.D. Giraud, K.D. Perkins, L. Muldoon, and B.H. Greenberg Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle J Cardiovasc Pharmacol 33 1999 433 439
15. J.H. Omens, H.A. Rockman, and J.W. Covell Passive ventricular mechanics in tight-skin mice Am J Physiol 266 1994 H1169 H1176
16. A. Yndestad, A.M. Holm, F. Muller, S. Simonsen, S.S. Froland, and L. Gullestad Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure Cardiovasc Res 60 2003 141 146
17. C.A. Heid, J. Stevens, K.J. Livak, and P.M. Williams Real time quantitative PCR Genome Res 6 1996 986 994
18. A.C. Staff, T. Ranheim, T. Henriksen, and B. Halvorsen 8-Iso-prostaglandin F-2 alpha reduces trophoblast invasion and matrix metalloproteinase activity Hypertension 35 2000 1307 1313
19. K.R. Chien, K.U. Knowlton, H. Zhu, and S. Chien Regulation of cardiac gene-expression during myocardial growth and hypertrophy-molecular studies of an adaptive physiologicalresponse FASEB J 5 1991 3037 3046
20. Y.Y. Li, C.F. McTiernan, and A.M. Feldman Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling Cardiovasc Res 46 2000 214 224
21. M. Sugano, M. Koyanagi, K. Tsuchida, T. Hata, and N. Makino In vivo gene transfer of soluble TNFalpha receptor 1 alleviates myocardial infarction FASEB J 16 2002
22. K.M. Kurrelmeyer, L.H. Michael, G. Baumgarten, G.E. Taffet, J.J. Peschon, and N. Sivasubramanian Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemicinduced apoptosis in a murine model of acute myocardial infarction Proc Natl Acad Sci U S A 97 2000 5456 5461
23. Kadokami T, McTiernan CF, Kubota T, Frye CS, Bounoutas GS, Robbins PD et al. Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. Am J Physiol Heart Circul Physiol 2001;280:H2281-2291.
24. Y.Y. Li, Y.Q. Feng, T. Kadokami, C.F. McTiernan, R. Draviam, and S.C. Watkins Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy [In Process Citation] Proc Natl Acad Sci U S A 97 2000 12746 12751
25. T. Kadokami, C. Frye, B. Lemster, C.L. Wagner, A.M. Feldman, and C.F. McTiernan Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model Circulation 104 2001 1094 1097
26. Y. Higuchi, C.F. McTiernan, C.B. Frye, B.S. McGowan, T.O. Chan, and A.M. Feldman Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy Circulation 109 2004 1892 1897
27. W.S. Bradham, B. Bozkurt, H. Gunasinghe, D. Mann, and F.G. Spinale Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective Cardiovasc Res 53 2002 822 830
28. S. Hayashidani, H. Tsutsui, M. Ikeuchi, T. Shiomi, H. Matsusaka, and T. Kubota Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction Am J Physiol Heart Circ Physiol 285 2003 H1229 H1235
29. C.M. Yu, G.L. Tipoe, L.K. Wing-Hon, and C.P. Lau Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction J Am Coll Cardiol 38 2001 1207 1215
30. 1 density in the post-MI heart J Mol Cell Cardiol 38 2005 505 515
31. D.L. Mann, J.J. McMurray, M. Packer, K. Swedberg, J.S. Borer, and W.S. Colucci Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL) Circulation 109 2004 1594 1602
32. E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, and J.T. Willerson Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure-results of the anti-TNF therapy against congestive heart failure (ATTACH) trial Circulation 107 2003 3133 3140
33. Y.Y. Li, T. Kadokami, P. Wang, C.F. McTiernan, and A.M. Feldman MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure Am J Physiol Heart Circ Physiol 282 2002 H983 H989